EXTRACELLULAR VESICLES PROFILE PREDICTS ENHANCED ANTI-TUMOR RESPONSE IN CAR T‑CELL–TREATED LYMPHOPROLIFERATIVE NEOPLASMS (SIE 2026) - Oct 6, 2026 - Abstract #SP057; "The main infused product was axi cel (n=21); tisa cel was used in 7, and brexu cel in 3 patients with mantle cell lymphoma...Lower levels of total EVs and CD146+ EVs at day +14 may reflect reduced systemic inflammation follow- ing CAR-T, while an elevated CD146+ LK EV/total LK EV ra- tio at day +10 indicates early activation of leukocytes in- volved in leukocyte–endothelial interactions. Together, these patterns suggest that early, targeted leukocyte–endothelial activation coupled with a lower inflammatory milieu might be associated with effective anti tumor response and im- proved PFS."
CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD31 • MCAM • PECAM1 • PTPRC
|
|
M. Dicataldo1,2; G. Lia2; A. Melis2; F. Cavallo1,2; S. Ragaini1,2; M. Clerico1; S. Ferrero1,2; T. Francisci3; M. Novo4; B. Botto4; A. Busca4; R. Freilone4; B. Bruno1,2; L. Giaccone1,2
|